Status on the use of anti-hypertensive drugs in the southwest areas of China
10.3760/cma.j.cn112338-20190627-00472
- VernacularTitle:我国西南地区高血压患者降压药物应用现状
- Author:
Danwei ZHANG
1
;
Lijuan SONG
;
Yan LI
;
Jiali SONG
;
Zhijie LIU
;
Jingwei YANG
;
Xin ZHENG
;
Haibo ZHANG
Author Information
1. 北京协和医学院 中国医学科学院阜外医院 国家心血管病中心 国家心血管疾病临床医学研究中心心血管疾病国家重点实验室，北京 100037
- Keywords:
Hypertension;
Anti-hypertensive drug;
Drug combination therapy;
Southwest China
- From:
Chinese Journal of Epidemiology
2020;41(4):520-525
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To understand the current status of anti-hypertensive drug use in patients with hypertension in the Southwest areas of China.Methods:Based on the Program of Screening and Intervention Subjects with High Risk Cardiovascular Diseases, this study presented information on adults aged 35-75 in Southwest China by convenient sampling method, from January 2016 to November 2018. Basic information and cardiovascular related data were collected. Data on hypertensive patients were recorded, including names, doses and frequency of anti-hypertensive drugs they used. Information on the use of anti-hypertensive drugs among different hypertension subgroups, potential related characteristics, types and combination patterns of drugs, etc., were analyzed. Results:A total of 394 957 subjects were included in the study, with 159 014 identified as being hypertensive [mean age (58.8±9.5) years, 40.2 % male]. 29.8 % of them ever received antihypertensive drugs. A total of 30 445 of the patients reported detailed information of the drugs they ever used and 22.5 % of them received therapy of combined drugs. Rates of using combination therapy were consistent among subgroups with different age, gender, blood pressure level and history of cardiovascular and cerebrovascular diseases. Results from the multivariate logistic regression analysis showed that patients with previous cardiovascular and cerebrovascular events, obesity or diabetes were more likely to have received combined therapy, while patients with less education or lower income were in the opposite. Calcium antagonists (58.6 %) were the main drugs being used in single drug therapy, while traditional fixed-dose combination drugs (31.4 %) were the most common ones in the drug-combination therapy, followed by angiotensin converting enzyme inhibitor/angiotensin receptor blocker combined with calcium antagonists (22.4 %). Angiotensin converting enzyme inhibitor/angiotensin receptor blocker combined with beta blocker was the main drug used in patients with coronary heart disease. Conclusions:Treatment programs using the antihypertensive drugs for hypertensive patients in Southwest China needs to be improved, since the irrational use of antihypertensive drugs still exists. However, we would encourage the use of combination therapy for hypertensive patients.
